Clinical Effects of Brentuximab VedotinBrentuximab vedotin was studied in people with Hodgkin's lymphoma and systemic ALCL. In these studies, 73 percent of people with Hodgkin's lymphoma who were given the medication had at least a 50 percent reduction in the size of their lymphoma tumors. In the systemic ALCL studies, 86 percent of people given brentuximab vedotin had their tumors shrink by at least half.
When and How to Receive This MedicationSome general considerations to keep in mind during treatment with brentuximab vedotin include the following:
- This medicine is given as a slow injection into a vein (known as an intravenous, or IV, infusion) every three weeks.
- It will take about 30 minutes to receive the brentuximab vedotin infusion. The infusion will be given by a healthcare provider in a healthcare setting, such as a hospital or clinic.
- Your healthcare provider may give you other medicines to take before administering the injection.
- Brentuximab vedotin should be inspected before use, and should not be given if the medicine contains particles or is discolored.
- For the medication to work properly, it must be used as prescribed. It is important to keep all of your appointments to receive your dose.
Dosing Information for Brentuximab VedotinThe dose of brentuximab vedotin your healthcare provider recommends will vary, based on a number of factors, including:
- Your weight
- How well you tolerate the medication.
As is always the case, do not adjust your dosage unless your healthcare provider specifically tells you to do so.
(Click Brentuximab Vedotin Dosage for more information.)